Journal
NATURE REVIEWS GENETICS
Volume 16, Issue 9, Pages 543-552Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nrg3978
Keywords
-
Categories
Funding
- Swedish Research Council
- US National Institutes of Health (NIH) [CA139444]
Ask authors/readers for more resources
Small interfering RNAs (siRNAs), which downregulate gene expression guided by sequence complementarity, can be used therapeutically to block the synthesis of disease-causing proteins. The main obstacle to siRNA drugs-their delivery into the target cell cytosol-has been overcome to allow suppression of liver gene expression. Here, we review the results of recent clinical trials of siRNA therapeutics, which show efficient and durable gene knockdown in the liver, with signs of promising clinical outcomes and little toxicity. We also discuss the barriers to more widespread applications that target tissues besides the liver and the most promising avenues to overcome them.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available